Welcome
Support Centre
07 August 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Effect of the recall software Impfdoc on vaccination rates among paediatricians
ISRCTN ISRCTN75503825
ClinicalTrials.gov identifier
Public title Effect of the recall software Impfdoc on vaccination rates among paediatricians
Scientific title
Acronym EERSV
Serial number at source N/A
Study hypothesis Children who are treated by paediatricians who use the recall software Impfdoc have higher vaccination rates than those treated by paediatricians not using the software.
Ethics approval Ethics Board of the Medical faculty, University of Munich. Approved on 04/04/2008 (Project no. 035-08)
Study design Cluster-randomised controlled trial.
Countries of recruitment Germany
Disease/condition/study domain Vaccination rates
Participants - inclusion criteria Paediatricians in Bavaria, Germany, and children treated by these paediatricians.
Participants - exclusion criteria Children switching paediatricians (only if paediatricians are not in same study group) within the study period.
Anticipated start date 01/08/2008
Anticipated end date 31/12/2010
Status of trial Ongoing
Patient information material
Target number of participants 200 paediatricians, 1600 children.
Interventions Paediatricians are offered the software Impfdoc and an instruction for the software free of charge. One group receives the software earlier (intervention group) and one group later (control group). The delay in the distribution of the software depends on the organisation of the instructions. The control group is expected to receive the software 3-6 months later.
Primary outcome measure(s) Proportion of children who received full immunisation until the age of 12 months according to the recommendations of the German standing committee on vaccinations (Ständige Impfkommission STIKO).
Secondary outcome measure(s) Proportion of children who have received their second dose of measles vaccination, assessed at the age of 2 years.
Sources of funding Institute for Medical Information (Institut für medizinische Information) (Germany)
Trial website
Publications
Contact name Prof  Rüdiger  von Kries
  Address Institut für Soziale Pädiatrie und Jugendmedizin
Heiglhofstr. 63
  City/town Munich
  Zip/Postcode 81377
  Country Germany
Sponsor Individual sponsor (Germany)
  Address Dr. med. Hans-Jürgen Schrörs
Institut für Medizinische Information
Staufenerstr. 36
  City/town Freiburg
  Zip/Postcode 79115
  Country Germany
  Tel +49 761 70700 34/ 23
  Email hj.schroers@inst4med.de
Date applied 16/04/2008
Last edited 16/05/2008
Date ISRCTN assigned 16/05/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central